ACOX1 destabilizes p73 to suppress intrinsic apoptosis pathway and regulates sensitivity to doxorubicin in lymphoma cells
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Lymphoma is one of the most curable types of cancer. However, drug resistance is the main challenge faced in lymphoma treatment. Peroxisomal acyl-CoA oxidase 1 (ACOX1) is the rate-limiting enzyme in fatty acid β-oxidation. Deregulation of ACOX1 has been linked to peroxisomal disorders and carcinogenesis in the liver. Currently, there is no information about the function of ACOX1 in lymphoma. In this study, we found that upregulation of ACOX1 promoted proliferation in lymphoma cells, while downregulation of ACOX1 inhibited proliferation and induced apoptosis. Additionally, overexpression of ACOX1 increased resistance to doxorubicin, while suppression of ACOX1 expression markedly potentiated doxorubicin-induced apoptosis. Interestingly, downregulation of ACOX1 promoted mitochondrial location of Bad, reduced mitochondrial membrane potential and provoked apoptosis by activating caspase-9 and caspase-3 related apoptotic pathway. Overexpression of ACOX1 alleviated doxorubicin-induced activation of caspase-9 and caspase-3 and decrease of mitochondrial membrane potential. Importantly, downregulation of ACOX1 increased p73, but not p53, expression. p73 expression was critical for apoptosis induction induced by ACOX1 downregulation. Also, overexpression of ACOX1 significantly reduced stability of p73 protein thereby reducing p73 expression. Thus, our study indicated that suppression of ACOX1 could be a novel and effective approach for treatment of lymphoma.
Abstract
Lymphoma is one of the most curable types of cancer. However, drug resistance is the main challenge faced in lymphoma treatment. Peroxisomal acyl-CoA oxidase 1 (ACOX1) is the rate-limiting enzyme in fatty acid β-oxidation. Deregulation of ACOX1 has been linked to peroxisomal disorders and carcinogenesis in the liver. Currently, there is no information about the function of ACOX1 in lymphoma. In this study, we found that upregulation of ACOX1 promoted proliferation in lymphoma cells, while downregulation of ACOX1 inhibited proliferation and induced apoptosis. Additionally, overexpression of ACOX1 increased resistance to doxorubicin, while suppression of ACOX1 expression markedly potentiated doxorubicin-induced apoptosis. Interestingly, downregulation of ACOX1 promoted mitochondrial location of Bad, reduced mitochondrial membrane potential and provoked apoptosis by activating caspase-9 and caspase-3 related apoptotic pathway. Overexpression of ACOX1 alleviated doxorubicin-induced activation of caspase-9 and caspase-3 and decrease of mitochondrial membrane potential. Importantly, downregulation of ACOX1 increased p73, but not p53, expression. p73 expression was critical for apoptosis induction induced by ACOX1 downregulation. Also, overexpression of ACOX1 significantly reduced stability of p73 protein thereby reducing p73 expression. Thus, our study indicated that suppression of ACOX1 could be a novel and effective approach for treatment of lymphoma.
참고문헌 (27)
- 허주령, "Epidemiologic overview of malignant lymphoma", Blood Research, 47(2), pp.92~104 (2012), 대한혈액학회[DOI]
- Smith A, "Lymphoma incidence, survival and prevalence 2004-2014 : sub-type analyses from the UK's Haematological Malignancy Research Network", Br J Cancer, 112, pp.1575~1584 (2015)
- Shanbhag S, "Hodgkin lymphoma : A review and update on recent progress", CA Cancer J Clin, 68, pp.116~132 (2018)
- Armitage JO, "Non-Hodgkin lymphoma", Lancet, 390, pp.298~310 (2017)
- Zeng J, "Expression and purification of his-tagged rat peroxisomal acyl-CoA oxidase I wild-type and E421 mutant proteins", Protein Expr Purif, 38, pp.153~160 (2004)
- Fournier B, "Large deletion of the peroxisomal acyl-CoA oxidase gene in pseudoneonatal adrenoleukodystrophy", J Clin Invest, 94, pp.526~531 (1994)
- Fan CY, "Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene", J Biol Chem, 271, pp.24698~24710 (1996)
- Fan CY, "Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism", J Biol Chem, 273, pp.15639~15645 (1998)
- Huang J, "Progressive endoplasmic reticulum stress contributes to hepatocarcinogenesis in fatty acyl-CoA oxidase 1-deficient mice", Am J Pathol, 179, pp.703~713 (2011)
- Melino G, "p73 : Friend or foe in tumorigenesis", Nat Rev Cancer, 2, pp.605~615 (2002)
- Oberst A, "Regulation of the p73 protein stability and degradation", Biochem Biophys Res Commun, 331, pp.707~712 (2005)
- Nemajerova A, "Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice", J Clin Invest, 120, pp.2070~2080 (2010)
- Zorova LD, "Mitochondrial membrane potential", Anal Biochem, 552, pp.50~59 (2018)
- Chao C, "Ser18 and 23phosphorylation is required for p53-dependent apoptosis and tumor suppression", EMBO J, 25, pp.2615~2622 (2006)
- Jones EV, "Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase", Biochem J, 405, pp.617~623 (2007)
- Antonenkov VD, "Peroxisomes are oxidative organelles", Antioxid Redox Signal, 13, pp.525~537 (2010)
- Dahabieh MS, "Peroxisomes and cancer : The role of a metabolic specialist in a disease of aberrant metabolism", Biochim Biophys Acta Rev Cancer, 1870, pp.103~121 (2018)
- Dahabieh MS, "Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis", Cell Death Differ, 24, pp.1912~1924 (2017)
- Ferdinandusse S, "Clinical, biochemical, and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency", Hum Mutat, 28, pp.904~912 (2007)
- Yu S, "Peroxisome proliferatoractivated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis", Curr Mol Med, 3, pp.561~572 (2003)
- Hashimoto T, "Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype", J Biol Chem, 274, pp.19228~19236 (1999)
- Rossi M, "The ubiquitin-protein ligase Itch regulates p73 stability", EMBO J, 24, pp.836~848 (2005)
- Miyazaki K, "A novel HECT-type E3 ubiquitin ligase, NEDL2, stabilizes p73 and enhances its transcriptional activity", Biochem Biophys Res Commun, 308, pp.106~113 (2003)
- Asher G, "A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73", Genes Dev, 19, pp.316~321 (2005)
- Agami R, "Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis", Nature, 399, pp.809~813 (1999)
- Zheng F, "Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype", Nat Commun, 7, pp.10180~ (2016)
- Zheng FM, "A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance", Mol Cancer Ther, 13, pp.1991~2003 (2014)